Danielson receives Terry Hoeppner Patient Advocacy Award
Hoosier Cancer Research Network, formerly known as Hoosier Oncology Group, recently honored Donald C. “Danny” Danielson with the 2013 Terry Hoeppner Patient Advocacy Award in […]
Hoosier Cancer Research Network, formerly known as Hoosier Oncology Group, recently honored Donald C. “Danny” Danielson with the 2013 Terry Hoeppner Patient Advocacy Award in […]
Hoosier Cancer Research Network is pleased to announce the opening of a cancer clinical trial for patients with stage III non-small cell lung cancer at […]
Hoosier Cancer Research Network mourns the loss of Donald C. “Danny” Danielson, who died this morning at his home in New Castle, Ind., at the […]
This spring, Hoosier Cancer Research Network Chairman Christopher A. Fausel, PharmD, offered a unique challenge to friends and supporters of HCRN. Combining his interest in […]
This month, Hoosier Cancer Research Network (HCRN) features our member West Cancer Center in Memphis, Tenn., and Daniel Vaena, MD, a medical oncologist and hematologist […]
HCRN Annual Report 2018 Hoosier cancer Research Network enjoys a unique synergy with our research collaborators that few others can claim. An Indiana-based nonprofit organization […]
Following is a cumulative list of Hoosier Cancer Research Network publications in bladder cancer.
The Bladder Cancer Advocacy Network (BCAN) and Paradigm today announced a partnership for the launch of a large-scale genomically-driven bladder cancer study. Hoosier Cancer Research […]
Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188 Status: Closed to Accrual
Hoosier Cancer Research Network, formerly known as Hoosier Oncology Group, recently honored Matthew Galsky, MD, as recipient of the Danny Danielson Translational Innovation Award. The […]
Hoosier Cancer Research Network, formerly known as Hoosier Oncology Group, recently honored Daniela Matei, MD, as the 2014 recipient of the George and Sarah Jane […]
Hoosier Cancer Research Network investigators presented the ongoing study LUN18-335, RAMOSE: An open-label randomized Phase II study of osimertinib with or without ramucirumab in TKI-naïve […]
Reposted with permission by the Indiana University School of Medicine. Indiana University School of Medicine researcher Bryan P. Schneider, MD, is leading a novel nationwide […]
A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With or Without Consolidation Docetaxel in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC): Hoosier […]
Richard Kim, MD, service chief of Medical Gastrointestinal Oncology and senior member in the Gastrointestinal Oncology Department at Moffitt Cancer Center, has been appointed as […]
Noah Hahn, MD, recently concluded his tenure as chief scientific officer of the Hoosier Oncology Group and associate professor of medicine at the Indiana University […]
A single arm phase II study, LUN15-299, for patients who have been previously treated for mesothelioma is being conducted by the Hoosier Cancer Research Network […]
Hoosier Cancer Research Network (HCRN), formerly known as Hoosier Oncology Group, joined nearly 30,000 of the world’s leading cancer experts in Chicago recently for the […]
A Phase II Trial of VP-16, Ifosfamide and Cisplatin (VIP) Combination Chemotherapy for Previously Untreated Extensive Small Cell Lung Cancer
A Phase I/II Study of Carboplatin/Nab-Paclitaxel and MK-3475 for Advanced Non-Small Cell Lung Cancer (NSCLC): HCRN LUN13-175
Facebook
Hoosier Cancer Research Network on Facebook
Linked In
You Tube
Twitter